The global male infertility market size was valued at USD 4.9 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 8.4 billion in 2033, at a CAGR of 7.1% from 2026 to 2033. Europe dominated the market, accounting for a revenue share of 37.0% in 2025. Increasing infertility rates across the globe and the adoption of assisted reproductive technologies (ARTs) are expected to drive the market for male infertility in the forthcoming years.
ARTs cover a wide spectrum of infertility treatments and offer solutions for males facing problems, such as low sperm count, abnormal sperm quality, and poor motility. Moreover, ARTs offer a higher success rate than medications. The market for male infertility is expected to witness significant growth in the future, owing to technological advancements in the field of assisted reproductive technologies. The integration of artificial intelligence, robotics, and advanced sperm selection technologies into assisted reproductive procedures is improving treatment precision and increasing the likelihood of successful fertilization. For instance, in April 2026, BAIBYS Fertility Ltd. announced the first confirmed pregnancy achieved using its autonomous AI-based robotic sperm selection system for IVF procedures. The technology uses artificial intelligence and robotics to identify and isolate high-quality sperm cells based on morphology and motility, highlighting the increasing integration of advanced technologies into assisted reproductive treatments.
Given the increasing emphasis on early and accurate diagnosis of male infertility, the adoption of advanced semen analysis and sperm quality assessment technologies is expected to grow steadily over the forecast period. Conventional semen analysis remains the primary diagnostic tool for evaluating male reproductive health, while emerging tests provide deeper insights into sperm function and fertility potential. For instance, in April 2026, Legacy launched its Basic Semen Analysis service at a price of USD 145, aiming to improve access to clinical-grade male fertility testing. The company also expanded access to sperm DNA fragmentation testing through its Advanced Semen Analysis offering, enabling a more comprehensive assessment of sperm quality beyond conventional parameters. Such developments are expected to enhance access to male infertility diagnostics, enable earlier intervention, and drive growth in the diagnostic segment.
An increase in the global prevalence of infertility is a significant clinical problem. Around 48 million couples suffer from infertility worldwide. Of all cases, about 20% to 30% of cases are due to male factor infertility. This may be due to one or more factors, such as abnormal morphology, low sperm concentration, and poor sperm motility. Hence, increasing male infertility and growing awareness regarding the same have further prompted the use of drugs, hormonal therapy, and ART. Alcohol intake, smoking, obesity, stress, and lifestyle changes are some of the major factors that can be attributed to infertility in males.
Continuous efforts in R&D are carried out for a better understanding of the idiopathic world of infertility. Hence, companies are investing in developing devices to identify the root cause and enable targeted treatment. Furthermore, the development and commercialization of hormonal therapy are likely to drive the market for male infertility during the forecast period. Governments in various countries have taken initiatives to improve reimbursement for infertility-related treatments. In addition, improved patient data safety resulting from standardized regulations is expected to increase patients' preference for infertility treatments.
▪ Canada
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Mexico
▪ Argentina
▪ Saudi Arabia
This product will be delivered within 1-3 business days.
ARTs cover a wide spectrum of infertility treatments and offer solutions for males facing problems, such as low sperm count, abnormal sperm quality, and poor motility. Moreover, ARTs offer a higher success rate than medications. The market for male infertility is expected to witness significant growth in the future, owing to technological advancements in the field of assisted reproductive technologies. The integration of artificial intelligence, robotics, and advanced sperm selection technologies into assisted reproductive procedures is improving treatment precision and increasing the likelihood of successful fertilization. For instance, in April 2026, BAIBYS Fertility Ltd. announced the first confirmed pregnancy achieved using its autonomous AI-based robotic sperm selection system for IVF procedures. The technology uses artificial intelligence and robotics to identify and isolate high-quality sperm cells based on morphology and motility, highlighting the increasing integration of advanced technologies into assisted reproductive treatments.
Given the increasing emphasis on early and accurate diagnosis of male infertility, the adoption of advanced semen analysis and sperm quality assessment technologies is expected to grow steadily over the forecast period. Conventional semen analysis remains the primary diagnostic tool for evaluating male reproductive health, while emerging tests provide deeper insights into sperm function and fertility potential. For instance, in April 2026, Legacy launched its Basic Semen Analysis service at a price of USD 145, aiming to improve access to clinical-grade male fertility testing. The company also expanded access to sperm DNA fragmentation testing through its Advanced Semen Analysis offering, enabling a more comprehensive assessment of sperm quality beyond conventional parameters. Such developments are expected to enhance access to male infertility diagnostics, enable earlier intervention, and drive growth in the diagnostic segment.
An increase in the global prevalence of infertility is a significant clinical problem. Around 48 million couples suffer from infertility worldwide. Of all cases, about 20% to 30% of cases are due to male factor infertility. This may be due to one or more factors, such as abnormal morphology, low sperm concentration, and poor sperm motility. Hence, increasing male infertility and growing awareness regarding the same have further prompted the use of drugs, hormonal therapy, and ART. Alcohol intake, smoking, obesity, stress, and lifestyle changes are some of the major factors that can be attributed to infertility in males.
Continuous efforts in R&D are carried out for a better understanding of the idiopathic world of infertility. Hence, companies are investing in developing devices to identify the root cause and enable targeted treatment. Furthermore, the development and commercialization of hormonal therapy are likely to drive the market for male infertility during the forecast period. Governments in various countries have taken initiatives to improve reimbursement for infertility-related treatments. In addition, improved patient data safety resulting from standardized regulations is expected to increase patients' preference for infertility treatments.
Global Male Infertility Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global male infertility market report based on test, treatment, and region:Test Outlook (Revenue, USD Billion, 2021 - 2033)
- DNA Fragmentation Technique
- Oxidative Stress Analysis
- Microscopic Examination
- Sperm Agglutination
- Computer-Assisted Semen Analysis
- Sperm Penetration Assay
- Others
Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
- Assisted Reproductive Technology and Varicocele Surgery
- Medication
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
▪ Canada
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
- Asia Pacific
▪ China
▪ India
▪ Australia
▪ South Korea
- Latin America
▪ Mexico
▪ Argentina
- Middle East & Africa
▪ Saudi Arabia
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
Chapter 4 Male Infertility Market: Test Analysis
Chapter 5 Male Infertility Market: Treatment Analysis
Chapter 6 Male Infertility Market: Regional Analysis
Chapter 7 Competitive Analysis
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- Andrology solutions
- Aytu BioPharma
- Cadila Pharmaceuticals
- Halotech DNA SL
- EMD Serono, Inc.
- SCSA Diagnostics
- Intas Pharmaceuticals Ltd.
